vs
ImmunityBio, Inc.（IBRX）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是ImmunityBio, Inc.的1.9倍（$71.1M vs $38.3M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -161.8%，领先163.8%），ImmunityBio, Inc.同比增速更快（407.0% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-71.3M）
ImmunityBio, Inc.是一家处于临床阶段的生物技术企业，专注开发针对多种癌症及传染性疾病的下一代免疫疗法与候选疫苗，核心研发方向涵盖细胞疗法、抗体药物及靶向疫苗平台，主要运营市场位于美国。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
IBRX vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.9倍
$38.3M
营收增速更快
IBRX
高出408.8%
-1.8%
净利率更高
RMAX
高出163.8%
-161.8%
自由现金流更多
RMAX
多$104.8M
$-71.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $71.1M |
| 净利润 | $-61.9M | $1.4M |
| 毛利率 | 99.0% | — |
| 营业利润率 | -169.0% | 13.1% |
| 净利率 | -161.8% | 2.0% |
| 营收同比 | 407.0% | -1.8% |
| 净利润同比 | -4.7% | -75.2% |
| 每股收益（稀释后） | $-0.06 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBRXRMAX
| Q4 25 | $38.3M | $71.1M | ||
| Q3 25 | $32.1M | $73.2M | ||
| Q2 25 | $26.4M | $72.8M | ||
| Q1 25 | $16.5M | $74.5M | ||
| Q4 24 | $7.6M | $72.5M | ||
| Q3 24 | $6.1M | $78.5M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $78.3M |
净利润IBRXRMAX
| Q4 25 | $-61.9M | $1.4M | ||
| Q3 25 | $-67.3M | $4.0M | ||
| Q2 25 | $-92.6M | $4.7M | ||
| Q1 25 | $-129.6M | $-2.0M | ||
| Q4 24 | $-59.2M | $5.8M | ||
| Q3 24 | $-85.7M | $966.0K | ||
| Q2 24 | — | $3.7M | ||
| Q1 24 | — | $-3.4M |
毛利率IBRXRMAX
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率IBRXRMAX
| Q4 25 | -169.0% | 13.1% | ||
| Q3 25 | -173.5% | 25.0% | ||
| Q2 25 | -269.8% | 19.3% | ||
| Q1 25 | -390.1% | 7.2% | ||
| Q4 24 | -919.0% | 5.9% | ||
| Q3 24 | -1314.3% | 19.4% | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | — | 5.8% |
净利率IBRXRMAX
| Q4 25 | -161.8% | 2.0% | ||
| Q3 25 | -209.8% | 5.4% | ||
| Q2 25 | -350.3% | 6.4% | ||
| Q1 25 | -784.9% | -2.6% | ||
| Q4 24 | -783.4% | 8.0% | ||
| Q3 24 | -1404.0% | 1.2% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | -4.3% |
每股收益（稀释后）IBRXRMAX
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $-0.08 | — | ||
| Q3 24 | $-0.14 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $242.8M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $-500.5M | $452.4M |
| 总资产 | $501.9M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资IBRXRMAX
| Q4 25 | $242.8M | $118.7M | ||
| Q3 25 | $257.8M | $107.5M | ||
| Q2 25 | $153.7M | $94.3M | ||
| Q1 25 | $61.6M | $89.1M | ||
| Q4 24 | $149.8M | $96.6M | ||
| Q3 24 | $130.4M | $83.8M | ||
| Q2 24 | — | $66.1M | ||
| Q1 24 | — | $82.1M |
总债务IBRXRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益IBRXRMAX
| Q4 25 | $-500.5M | $452.4M | ||
| Q3 25 | $-524.3M | $448.1M | ||
| Q2 25 | $-570.7M | $442.4M | ||
| Q1 25 | $-591.4M | $433.5M | ||
| Q4 24 | $-489.1M | $429.5M | ||
| Q3 24 | $-745.1M | $423.1M | ||
| Q2 24 | — | $418.4M | ||
| Q1 24 | — | $412.0M |
总资产IBRXRMAX
| Q4 25 | $501.9M | $582.5M | ||
| Q3 25 | $519.0M | $582.2M | ||
| Q2 25 | $402.1M | $574.8M | ||
| Q1 25 | $303.8M | $571.4M | ||
| Q4 24 | $382.9M | $581.6M | ||
| Q3 24 | $364.6M | $578.6M | ||
| Q2 24 | — | $571.4M | ||
| Q1 24 | — | $566.7M |
负债/权益比IBRXRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.4M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-71.3M | $33.5M |
| 自由现金流率自由现金流/营收 | -186.2% | 47.1% |
| 资本支出强度资本支出/营收 | 2.4% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-308.8M | $56.8M |
8季度趋势，按日历期对齐
经营现金流IBRXRMAX
| Q4 25 | $-70.4M | $40.9M | ||
| Q3 25 | $-68.9M | $17.7M | ||
| Q2 25 | $-79.7M | $4.6M | ||
| Q1 25 | $-85.9M | $5.7M | ||
| Q4 24 | $-85.1M | $59.7M | ||
| Q3 24 | $-98.8M | $17.6M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | — | $9.4M |
自由现金流IBRXRMAX
| Q4 25 | $-71.3M | $33.5M | ||
| Q3 25 | $-69.6M | $16.4M | ||
| Q2 25 | $-80.8M | $2.9M | ||
| Q1 25 | $-87.0M | $4.0M | ||
| Q4 24 | $-87.3M | $53.0M | ||
| Q3 24 | $-101.6M | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率IBRXRMAX
| Q4 25 | -186.2% | 47.1% | ||
| Q3 25 | -217.2% | 22.4% | ||
| Q2 25 | -305.9% | 4.0% | ||
| Q1 25 | -526.9% | 5.3% | ||
| Q4 24 | -1155.4% | 73.2% | ||
| Q3 24 | -1663.2% | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度IBRXRMAX
| Q4 25 | 2.4% | 10.4% | ||
| Q3 25 | 2.3% | 1.8% | ||
| Q2 25 | 4.1% | 2.2% | ||
| Q1 25 | 6.8% | 2.3% | ||
| Q4 24 | 28.0% | 9.1% | ||
| Q3 24 | 45.7% | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率IBRXRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBRX
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
